Abstract 4558
Background
Response of desmoid tumors (DT) to chemotherapy (CT) is evaluated according to RECIST criteria in daily practice and clinical trials. However, MRI demonstrates early change in heterogeneity in responding tumor, due to decrease in cellular area and increase in fibro-necrotic content, before dimensional response. Heterogeneity can be quantified through radiomics approach. Aim was to develop radiomics-based response criteria and to compare their performances with usual criteria.
Methods
43 patients (28 women, median age: 38.2) were prospectively included in this ancillary multicentre study of a randomized phase II trial (NCT01876082) as they presented with progressive DT, contrast-enhanced MRI at baseline (MRI-0) and early evaluation (3 months later, MRI-1). After signal intensities normalization, voxel size standardization and segmentation of whole DT volume on fat-suppressed contrast-enhanced T1-weighted imaging, 90 baseline and delta 3D-radiomics features (RF) were extracted. Using least absolute shrinkage and selection operator with Cox regression model and cross validation, a radiomics score based on selected and weighted RF was generated. The performances of prognostic models based on radiomics score, RECIST, mRECIST, EASL, Cheson, Choi and modified-Choi criteria from MRI-0 to MRI-1 to predict progression-free survival (PFS) were assessed with concordance-index. All the results were adjusted for ECOG performance status, initial tumor volume, prior CTs, current CT and B-catenin mutation. Usual response criteria were evaluated in both disease control and objective response settings.
Results
There were 11 progressions. The radiomics score included 4 variables (1 baseline RF and 3 delta-RF). A high radiomics score indicated a poorer prognosis. The radiomics score significantly correlated with PFS (adjusted hazard ratio = 3.39, 95%CI = [1.47-7.79], p = 0.0043) while none of the usual response criteria was (range of p-values = [0.166-0.750]). The prognostic model based on radiomics score had the highest concordance-index (0.794, 95%CI = [0.678-0.910]).
Conclusions
Quantifying heterogeneity with MRI at baseline and its early change through a dedicated radiomics score can improve the response evaluation for DT treated with CT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Antoine Italiano.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1496 - Randomized, double-blind, cross-over Phase I study comparing pharmacokinetics, pharmacodynamics, safety and immunogenicity of a biosimilar pegfilgrastim with EU and US references
Presenter: Maria Velinova
Session: Poster Display session 1
Resources:
Abstract
3993 - Prophylaxis with Lipegfilgrastim in patients with primary breast cancer receiving dose dense chemotherapy: results from the German NIS NADENS
Presenter: Marion Kiechle
Session: Poster Display session 1
Resources:
Abstract
3471 - Randomized phase 2 trial evaluating the safety of peripherally inserted central catheters vs implanted port catheters during adjuvant chemotherapy in early breast cancer patients.
Presenter: Florian Clatot
Session: Poster Display session 1
Resources:
Abstract
1327 - Simultaneous intravenous fluid infusion to prevent oxaliplatin infusion-related venous pain
Presenter: Stefan Van Ravensteijn
Session: Poster Display session 1
Resources:
Abstract
5004 - Clinical practice evaluation of opioids induced constipation management in cancer patients: The EIO-Praxis project.
Presenter: Enrique Aranda Aguilar
Session: Poster Display session 1
Resources:
Abstract
2222 - Analysis of the efficacy of naloxegol in a real-world 12 weeks of follow-up study, in patients with cancer and opioid-induced constipation with laxative-inadequate response.
Presenter: Manuel Cobo Dols
Session: Poster Display session 1
Resources:
Abstract
5556 - Consensus on strategies in the management of opioid-induced constipation in cancer patients
Presenter: Regina Girones Sarrio
Session: Poster Display session 1
Resources:
Abstract
3913 - Effect of Chinese Herbal Compound LC09 on Patients With Capecitabine-Associated Hand-Foot Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
Presenter: Yanni Lou
Session: Poster Display session 1
Resources:
Abstract
2208 - A prospective study about the complementary medicine among patients with cancers
Presenter: Wala Ben Kridis
Session: Poster Display session 1
Resources:
Abstract
1082 - Prevalence and management of Potentially Inappropriate Medication use and Potential Omissions in Medication in older cancer patients - the PIM POM study
Presenter: Fianne van Loveren
Session: Poster Display session 1
Resources:
Abstract